Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Nicola C. Day"'
Autor:
Nicola C. Day, Subramanya Kumar, Gerard Criner, Mark Dransfield, David M. G. Halpin, MeiLan K. Han, C. Elaine Jones, Morrys C. Kaisermann, Sally Kilbride, Peter Lange, David A. Lomas, Neil Martin, Fernando J. Martinez, Dave Singh, Robert Wise, David A. Lipson
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-12 (2020)
Abstract Background This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI dual therapy. Methods IMPACT was a 5
Externí odkaz:
https://doaj.org/article/bc54e68176db4ca5a7f7fcc01003961a
Autor:
Robert A. Wise, Mona Bafadhel, Courtney Crim, Gerard J. Criner, Nicola C. Day, David M.G. Halpin, MeiLan K. Han, Peter Lange, David A. Lipson, Fernando J. Martinez, Diego J. Maselli, Dawn Midwinter, Dave Singh, Maeva Zysman, Mark T. Dransfield, Richard E.K. Russell
Publikováno v:
European Respiratory Review, Vol 30, Iss 162 (2021)
Inhaled corticosteroids (ICS) have a class effect of increasing pneumonia risk in patients with COPD. However, pneumonia incidence varies widely across clinical trials of ICS use in COPD. This review clarifies methodological differences in defining a
Externí odkaz:
https://doaj.org/article/d3cb3ba2c1014707b22a384092f3fa36
Autor:
Neil R.W. Martin, C. Elaine Jones, Peter Lange, Nicola C. Day, Fernando J. Martinez, David A. Lomas, David M.G. Halpin, Sally Kilbride, Dave Singh, Morrys C. Kaisermann, David A. Lipson, Gerard J. Criner, MeiLan K. Han, Mark T. Dransfield, Robert A. Wise, Subramanya Kumar
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-12 (2020)
Day, N C, Kumar, S, Criner, G, Dransfield, M, Halpin, D M G, Han, M K, Jones, C E, Kaisermann, M C, Kilbride, S, Lange, P, Lomas, D A, Martin, N, Martinez, F J, Singh, D, Wise, R & Lipson, D A 2020, ' Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD : results on cardiovascular safety from the IMPACT trial ', Respiratory research, vol. 21 . https://doi.org/10.1186/s12931-020-01398-w
Respiratory Research
Day, N C, Kumar, S, Criner, G, Dransfield, M, Halpin, D M G, Han, M K, Jones, C E, Kaisermann, M C, Kilbride, S, Lange, P, Lomas, D A, Martin, N, Martinez, F J, Singh, D, Wise, R & Lipson, D A 2020, ' Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD : results on cardiovascular safety from the IMPACT trial ', Respiratory research, vol. 21 . https://doi.org/10.1186/s12931-020-01398-w
Respiratory Research
Background This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI dual therapy. Methods IMPACT was a 52-week, r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b15e5fac01e9768a179a6710488b0f87
http://link.springer.com/article/10.1186/s12931-020-01398-w
http://link.springer.com/article/10.1186/s12931-020-01398-w
Autor:
David M.G. Halpin, Robert A. Wise, Dawn Midwinter, Diego J. Maselli, Mark T. Dransfield, Courtney Crim, Maeva Zysman, Peter Lange, MeiLan K. Han, Mona Bafadhel, Fernando J. Martinez, Dave Singh, David A. Lipson, Richard Russell, Nicola C. Day, Gerard J. Criner
Publikováno v:
European Respiratory Review, Vol 30, Iss 162 (2021)
Wise, R A, Bafadhel, M, Crim, C, Criner, G J, Day, N C, Halpin, D M G, Han, M L K, Lange, P, Lipson, D A, Martinez, F J, Maselli, D J, Midwinter, D, Singh, D, Zysman, M, Dransfield, M T & Russell, R E K 2021, ' Discordant diagnostic criteria for pneumonia in COPD trials : a review ', European respiratory review : an official journal of the European Respiratory Society, vol. 30, no. 162, 210124 . https://doi.org/10.1183/16000617.0124-2021
Wise, R A, Bafadhel, M, Crim, C, Criner, G J, Day, N C, Halpin, D M G, Han, M L K, Lange, P, Lipson, D A, Martinez, F J, Maselli, D J, Midwinter, D, Singh, D, Zysman, M, Dransfield, M T & Russell, R E K 2021, ' Discordant diagnostic criteria for pneumonia in COPD trials : a review ', European respiratory review : an official journal of the European Respiratory Society, vol. 30, no. 162, 210124 . https://doi.org/10.1183/16000617.0124-2021
Inhaled corticosteroids (ICS) have a class effect of increasing pneumonia risk in patients with COPD. However, pneumonia incidence varies widely across clinical trials of ICS use in COPD. This review clarifies methodological differences in defining a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d25c1b75a125da6172fb0ac3323b2d
https://pubmed.ncbi.nlm.nih.gov/34789465
https://pubmed.ncbi.nlm.nih.gov/34789465
Autor:
Nicola C. Day, David M.G. Halpin, Dave Singh, Sally Kilbride, MeiLan K. Han, Mark T. Dransfield, David C. LaFon, Peter Lange, Robert A. Wise, Courtney Crim, Fernando J. Martinez, Gerard J. Criner, David A. Lomas, C. Elaine Jones, David A. Lipson, Neil R.W. Martin
Publikováno v:
Dransfield, M T, Crim, C, Criner, G J, Day, N C, Halpin, D M G, Han, M K, Jones, C E, Kilbride, S, LaFon, D, Lipson, D A, Lomas, D A, Martin, N, Martinez, F J, Singh, D, Wise, R A & Lange, P 2021, ' Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT ', Annals of the American Thoracic Society, vol. 18, no. 5, pp. 788-798 . https://doi.org/10.1513/AnnalsATS.202002-096OC
Annals of the American Thoracic Society
Annals of the American Thoracic Society
Rationale: In the IMPACT (Informing the Pathway of COPD Treatment) trial, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy reduced exacerbation risk versus FF/VI and UMEC/VI and mortality risk versus UMEC/VI. How
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aac24f024df70b92231a9b6090ad06d3
https://curis.ku.dk/portal/da/publications/risk-of-exacerbation-and-pneumonia-with-singleinhaler-triple-versus-dual-therapy-in-impact(e7249d02-9359-4fc8-aab7-cb3bbeef4130).html
https://curis.ku.dk/portal/da/publications/risk-of-exacerbation-and-pneumonia-with-singleinhaler-triple-versus-dual-therapy-in-impact(e7249d02-9359-4fc8-aab7-cb3bbeef4130).html
Autor:
Fernando J. Martinez, Gerard J. Criner, Sally Kilbride, Andrea Morris, Neil R.W. Martin, MeiLan K. Han, C. Elaine Jones, Steven Pascoe, Dawn Midwinter, Courtney Crim, David A. Lipson, David M.G. Halpin, Peter Lange, Dave Singh, Mark T. Dransfield, David A. Lomas, Nicola C. Day, Sally Lettis, Pamela Manchester, Robert A. Wise
Publikováno v:
American Journal of Respiratory and Critical Care Medicine
Lipson, D A, Crim, C, Criner, G J, Day, N C, Dransfield, M T, Halpin, D M G, Han, M K, Jones, C E, Kilbride, S, Lange, P, Lomas, D A, Lettis, S, Manchester, P, Martin, N, Midwinter, D, Morris, A, Pascoe, S J, Singh, D, Wise, R A & Martinez, F J 2020, ' Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease ', American Journal of Respiratory and Critical Care Medicine, vol. 201, no. 12, pp. 1508-1516 . https://doi.org/10.1164/rccm.201911-2207OC
Lipson, D A, Crim, C, Criner, G J, Day, N C, Dransfield, M T, Halpin, D M G, Han, M K, Jones, C E, Kilbride, S, Lange, P, Lomas, D A, Lettis, S, Manchester, P, Martin, N, Midwinter, D, Morris, A, Pascoe, S J, Singh, D, Wise, R A & Martinez, F J 2020, ' Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease ', American Journal of Respiratory and Critical Care Medicine, vol. 201, no. 12, pp. 1508-1516 . https://doi.org/10.1164/rccm.201911-2207OC
Rationale: The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dfba0f7db97ade9faad3541d0e22f1d
https://pubmed.ncbi.nlm.nih.gov/33444516
https://pubmed.ncbi.nlm.nih.gov/33444516
Autor:
Steven Pascoe, Fernando J. Martinez, David A. Lipson, Dmg Halpin, G.J. Criner, Mark T. Dransfield, C.E. Jones, Robert A. Wise, Dave Singh, Sally Kilbride, MeiLan K. Han, Andrea Morris, David A. Lomas, Dawn Midwinter, Peter Lange, Nicola C. Day, P. Manchester
Publikováno v:
A102. COPD: THERAPY.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0a4147cbf74c9addec4fc19dbf1489f
https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7344
https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7344
Autor:
Robert A. Wise, Steve Pascoe, Maggie Tabberer, David M.G. Halpin, David A. Lomas, Mark T. Dransfield, MeiLan K. Han, Dave Singh, Gerard J. Criner, Peter Lange, Fernando J. Martinez, Nicola C. Day, C. Elaine Jones, Sally Kilbride, David A. Lipson
Publikováno v:
Airway pharmacology and treatment.
Purpose: A post-hoc analysis of the IMPACT study in the subgroup of patients taking triple therapy at screening. The effect of ICS and LAMA step down was analyzed by comparing triple therapy vs dual therapy for rate of exacerbations (exb), change in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9550df87b367e38ab3f44f1c51151a13
https://doi.org/10.1183/13993003.congress-2018.oa2129
https://doi.org/10.1183/13993003.congress-2018.oa2129
Autor:
Dave Singh, MeiLan K. Han, Jean Brooks, Robert A. Wise, Peter Lange, Frank Barnhart, Mark T. Dransfield, Steven Pascoe, Gerard J. Criner, Sally Kilbride, Maggie Tabberer, C. Elaine Jones, David M.G. Halpin, Fernando J. Martinez, Noushin Brealey, David A. Lipson, Nicola C. Day, David A. Lomas
Publikováno v:
Singh, D & IMPACT Investigators 2018, ' Once-Daily Single Inhaler Triple Versus Dual Therapy in Patients with COPD ', The New England Journal of Medicine, vol. 378, pp. 1671-1678 . https://doi.org/10.1056/NEJMoa1713901
BACKGROUND The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA), as compared with dual therapy (either inhaled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fe513b685de585e3499bc8a274f6806
https://pubmed.ncbi.nlm.nih.gov/30440069
https://pubmed.ncbi.nlm.nih.gov/30440069
Autor:
Jane Z. Reed, Julie C. Barnes, Denis Fourches, Paul Bradley, Nicola C. Day, Alexander Tropsha
Publikováno v:
Chemical Research in Toxicology. 23:171-183
Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental drug discovery projects toward safer medicines. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dee943e427dcb7354d8a2323375fb472
https://doi.org/10.1021/tx900326k
https://doi.org/10.1021/tx900326k